CDCES Exam Flashcards

Q: What is the CDCES exam pass rate?

The CDCES exam has a 72% first-time pass rate, based on CBDCE's summary exam statistics for July 2024-June 2025. To pass, candidates must reach a scaled score of 70 on a 0-99 scale, an equated score rather than a fixed percentage of items correct.

Q: How many questions are on the CDCES exam and how long is it?

The CDCES exam has 175 multiple-choice questions total: 150 scored and 25 unscored pretest items that cannot be distinguished during the exam. Candidates have 4 hours to complete it, at a PSI test center or via Live Remote Proctoring.

Q: What are the eligibility requirements for the CDCES exam?

Candidates need a current active professional license in a qualifying discipline, 2 years of general work experience (1 year with a relevant master's degree), 1,000 hours of diabetes care and education (DCE) experience within the prior 5 years (at least 200 of those hours, or 20%, in the most recent year), and 15 continuing education hours in diabetes within the prior 2 years.

Q: What domains are tested on the CDCES exam?

The July 2024 Exam Content Outline weights 150 scored items across three domains: Assessment (37 items, 25%), Care and Education Interventions (105 items, 70% — the highest-yield domain by far), and Standards and Practices (8 items, 5%).

Q: What is the ADCES7 framework and why does it matter for the exam?

The ADCES7 Self-Care Behaviors — Healthy Coping, Healthy Eating, Being Active, Taking Medication, Monitoring, Reducing Risk, and Problem Solving — organizes Domain II.C, Person-Centered Education, the single largest sub-area on the exam at 58 of 150 scored items.

Q: How long is the CDCES certification valid?

CDCES certification is valid for a 5-year cycle, with the expiration date always falling on December 31 of the final year in the cycle, regardless of when in the year the exam was passed. Recertification is documentation-based, built on continued practice and continuing education.

Question 1

C-peptide test in distinguishing diabetes type

Accepted Answer

A low or undetectable C-peptide indicates minimal endogenous insulin production, consistent with type 1 diabetes or long-standing type 2 diabetes. A normal-to-high C-peptide with obesity, insulin resistance, and negative autoantibodies points to type 2 diabetes.

Question 2

Islet autoantibody panel

Accepted Answer

GAD65, IA-2, insulin autoantibodies (IAA), and ZnT8 are the four islet autoantibodies used to identify type 1 diabetes and LADA when the clinical picture is ambiguous (e.g., normal-BMI adult with rapid progression to insulin dependence).

Question 3

Teach-back method

Accepted Answer

A health-literacy confirmation technique in which the person restates education in their own words so the educator can verify understanding and correct gaps, rather than simply asking 'Do you understand?'

Question 4

Transtheoretical Model (Stages of Change)

Accepted Answer

Describes behavior change as moving through precontemplation, contemplation, preparation, action, and maintenance, with relapse possible at any stage; used to assess a person's readiness to change a self-care behavior.

Question 5

Assessing cost-related non-adherence

Accepted Answer

A direct question such as 'Have you ever cut back on medication or supplies because of cost?' should be asked at every visit; cost-related non-adherence, including deliberate insulin rationing, can change medication selection and prompt referral to a patient-assistance program.

Question 6

ADA diagnostic criteria for diabetes (any one, confirmed by repeat testing)

Accepted Answer

A1C ≥6.5% (≥48 mmol/mol); fasting plasma glucose ≥126 mg/dL (no caloric intake ≥8 hr); 2-hour plasma glucose ≥200 mg/dL on a 75-g OGTT; or random plasma glucose ≥200 mg/dL plus classic hyperglycemia symptoms or a hyperglycemic crisis.

Question 7

Prediabetes diagnostic criteria

Accepted Answer

A1C 5.7-6.4%; impaired fasting glucose (IFG) = FPG 100-125 mg/dL; impaired glucose tolerance (IGT) = 2-hour OGTT 140-199 mg/dL. A person can meet more than one criterion at once.

Question 8

Type 1 vs. type 2 diabetes pathophysiology

Accepted Answer

Type 1: T-cell-mediated autoimmune destruction of pancreatic beta cells causing absolute insulin deficiency. Type 2: insulin resistance in muscle/liver/fat plus progressive, relative (not absolute) insulin deficiency from beta-cell dysfunction.

Question 9

LADA vs. MODY

Accepted Answer

LADA ('type 1.5'): slower-onset autoimmune beta-cell destruction presenting in adulthood, usually GAD65-antibody positive, may not need insulin at diagnosis but progresses to insulin dependence. MODY: monogenic, autosomal-dominant, onset typically before age 25; GCK-MODY is mild/stable, HNF1A-MODY is progressive and sulfonylurea-sensitive.

Question 10

Dawn phenomenon vs. Somogyi effect

Accepted Answer

Both cause unexplained morning hyperglycemia. Dawn phenomenon: 2-3 AM glucose is normal or rising (nocturnal growth hormone/cortisol surge) — fix by adjusting basal insulin timing/dose. Somogyi effect: 2-3 AM glucose is low, then rebounds — fix by REDUCING evening insulin, not increasing it.

Question 11

General A1C target for most nonpregnant adults

Accepted Answer

A1C <7% (<53 mmol/mol), individualized — more stringent (e.g., <6.5%) for shorter disease duration/long life expectancy/no CVD if achievable safely; less stringent (e.g., <8%) for limited life expectancy, extensive comorbidities, or history of severe hypoglycemia.

Question 12

ADA preprandial and postprandial capillary glucose targets

Accepted Answer

Preprandial (before-meal) capillary plasma glucose: 80-130 mg/dL. Peak postprandial glucose (measured 1-2 hours after the start of the meal): <180 mg/dL. Paired with an A1C goal of <7% for most nonpregnant adults.

Question 13

CGM-based Time in Range (TIR) targets, most nonpregnant adults

Accepted Answer

Time in Range (70-180 mg/dL): >70%. Time Below Range Level 1 (<70 mg/dL): <4%. Time Below Range Level 2 (<54 mg/dL): <1%. Time Above Range Level 1 (>180 mg/dL): <25%. Time Above Range Level 2 (>250 mg/dL): <5%.

Question 14

Glucose Management Indicator (GMI)

Accepted Answer

GMI (%) = 3.31 + 0.02392 x mean CGM glucose (mg/dL). Requires a minimum of 14 days of CGM data, ideally with the sensor active at least 70% of the time, to be considered representative. GMI can diverge from lab A1C.

Question 15

Blood pressure and LDL goals for people with diabetes

Accepted Answer

BP goal: <130/80 mmHg if safely attainable (more intensive <120 mmHg systolic for high CV/kidney risk). LDL goal: <70 mg/dL with 1+ ASCVD risk factors (high-intensity statin); <55 mg/dL with established ASCVD (high-intensity statin, at least 50% reduction from baseline).

Question 16

The ADCES7 Self-Care Behaviors

Accepted Answer

Healthy Coping, Healthy Eating, Being Active, Taking Medication, Monitoring, Reducing Risk, and Problem Solving. Healthy Coping is positioned at the center of the framework because sustained engagement with the other six depends on emotional/psychological capacity to cope with a chronic condition.

Question 17

SMART goals

Accepted Answer

Specific, Measurable, Achievable, Relevant, and Time-bound. Written collaboratively, in the person's own words, and typically behavior-by-behavior (e.g., a Being Active goal is distinct from a Taking Medication goal) as part of the Individualized Education Plan.

Question 18

National Standards for DSMES (NSDSMES) — current structure

Accepted Answer

The 2022 revision consolidated the National Standards from 10 standards (2017 edition) to 6 broader standards: Support for DSMES Services, Population and Service Assessment, DSMES Team, Delivery and Design of DSMES Services, Person-Centered DSMES, and Measuring/Demonstrating Outcomes.

Question 19

The Four Critical Times to assess DSMES need

Accepted Answer

1) At diagnosis, 2) annually and/or when not meeting treatment targets, 3) when complicating factors develop, 4) when transitions in life or care occur (new care team, insurance change, pediatric-to-adult transition). Medicare's DSMT benefit covers up to 10 hours in the first year and 2 hours/year thereafter.

Question 20

Carbohydrate choice (carb serving)

Accepted Answer

Defined as 15 grams of carbohydrate (e.g., one slice of bread, one small piece of fruit, 1/3 cup cooked rice, 1 cup milk). For insulin-dose calculation, carbohydrate GRAM counting from the Nutrition Facts 'Total Carbohydrate' line is used instead of counting choices.

Question 21

Insulin-to-carbohydrate ratio — Rule of 500

Accepted Answer

ICR = 500 / Total Daily Dose (TDD) of insulin. Example: TDD of 50 units → 500/50 = 10, so 1 unit of rapid-acting insulin covers about 10 grams of carbohydrate. This is a starting-point estimate that must be verified and re-titrated with glucose data.

Question 22

Correction factor (insulin sensitivity factor) — Rule of 1800 / 1500

Accepted Answer

Correction factor = 1800 / TDD for rapid-acting insulin (1500 / TDD for regular/short-acting). Example: TDD of 60 units → 1800/60 = 30, so 1 unit of rapid-acting insulin is expected to lower glucose by about 30 mg/dL.

Question 23

Nonnutritive sweeteners vs. sugar alcohols

Accepted Answer

Nonnutritive sweeteners (FDA-approved: saccharin, aspartame, acesulfame potassium, sucralose, neotame, advantame; GRAS: stevia, monk fruit) provide little/no calories or carbs. Sugar alcohols (erythritol, xylitol, sorbitol, mannitol, maltitol) are NOT calorie-free — about 2 kcal/g with a partial carb/glycemic effect and possible GI upset.

Question 24

ADA/ACSM aerobic and resistance activity targets

Accepted Answer

Aerobic: ≥150 minutes/week moderate-to-vigorous intensity over ≥3 days/week, no more than 2 consecutive days without activity (≥75 min/week vigorous/interval may suffice if already fit). Resistance training: 2-3 sessions/week on nonconsecutive days. Interrupt prolonged sitting every 30 minutes.

Question 25

Pre-exercise glucose and ketone safety check

Accepted Answer

Glucose <90 mg/dL: eat 15-30 g fast-acting carb first, recheck in ~15 min. 90-250 mg/dL: proceed. >250 mg/dL with negative ketones: proceed with caution. 250-349 mg/dL WITH ketones, or ≥350 mg/dL regardless: do NOT exercise — correct hyperglycemia/ketosis first.

Question 26

Delayed-onset (post-exercise) hypoglycemia

Accepted Answer

Can occur many hours after activity, including overnight, as muscle/liver glycogen stores replenish and insulin sensitivity stays elevated. Teach a post-exercise glucose check, a bedtime snack, and CGM trend review before sleep.

Question 27

Rapid-acting insulin analogs (lispro, aspart, glulisine)

Accepted Answer

Onset 10-15 min, peak 60-90 min, duration 3-5 hr. Dosed 0-15 minutes before a meal. Standard choice for mealtime/bolus dosing, correction doses, and the only insulin used in pumps and hybrid closed-loop systems.

Question 28

Regular (short-acting) human insulin

Accepted Answer

Onset ~30 min, peak 2-3 hr, duration 6-8 hr. Dosed about 30 minutes before a meal. The only insulin approved for IV administration — the formulation used to treat DKA and HHS in the hospital.

Question 29

NPH insulin

Accepted Answer

Onset 1-2 hr, peak 4-12 hr, duration 12-18 hr. A cloudy suspension that must be gently rolled/inverted (never shaken) before dosing. The only commonly used basal insulin with a pronounced peak — a classic testable cause of nocturnal or mid-afternoon hypoglycemia if mistimed.

Question 30

Long-acting and ultra-long-acting basal analogs

Accepted Answer

Glargine and detemir: onset 1-2 hr, no pronounced peak, duration up to 24 hr. Degludec: onset ~1 hr, no pronounced peak, duration >42 hr — the longest-acting basal insulin available, with the flattest action profile.

Question 31

U-500 regular insulin

Accepted Answer

Five times the concentration of U-100 regular insulin; reserved for severe insulin resistance requiring more than 200 units/day. Behaves with BOTH prandial and basal characteristics. Must never be drawn up with a standard U-100 syringe and is not approved for standard insulin pumps — a recognized high-severity medication-error risk.

Question 32

Metformin

Accepted Answer

First-line therapy for type 2 diabetes; reduces hepatic glucose production. GI effects (nausea, diarrhea) occur in ~20-30% of new users. B12 deficiency develops in ~5-10% of long-term users. Contraindicated at eGFR <30 mL/min/1.73 m²; not recommended to initiate at eGFR 30-45.

Question 33

GLP-1 receptor agonists and dual GIP/GLP-1 agonist (tirzepatide)

Accepted Answer

Glucose-dependent insulin release, reduced glucagon, slowed gastric emptying; produce substantial weight loss (greatest with tirzepatide) and reduce major cardiovascular events in several agents. Carry an FDA BOXED WARNING against use with personal/family history of medullary thyroid carcinoma (MTC) or MEN2. Avoid with history of pancreatitis.

Question 34

SGLT2 inhibitors

Accepted Answer

Block renal glucose reabsorption, causing glucosuria; provide cardiovascular, heart-failure, and renal benefit independent of glycemic control. Key risks: genital mycotic infection (most common) and euglycemic DKA (glucose often <200 mg/dL) — ketones must be checked with any DKA symptoms regardless of glucose level. Hold before surgery/during acute illness.

Question 35

Sulfonylureas

Accepted Answer

Stimulate insulin secretion from beta cells independent of glucose level, giving the HIGHEST hypoglycemia risk of any oral agent, plus weight gain. Glyburide carries the highest risk within the class, especially in older adults or renal impairment.

Question 36

Correct SMBG (fingerstick) technique

Accepted Answer

Wash and dry hands before testing (residual sugar falsely elevates results), warm the hand to improve blood flow, use the side of the fingertip (less pain), and apply an adequate first drop rather than 'milking' the finger, which dilutes the sample with tissue fluid.

Question 37

Real-time CGM (rtCGM) vs. intermittently scanned CGM (isCGM)

Accepted Answer

rtCGM streams data continuously to a receiver/smartphone with customizable high/low alarms. isCGM ('flash' monitoring) stores data that the user retrieves by scanning the sensor. Most current sensors are worn 10-15 days.

Question 38

Time in Range (TIR)

Accepted Answer

Percentage of a 24-hour day with glucose 70-180 mg/dL. Goal for most adults: >70% (~17 hours/day), which correlates with an A1C of roughly 7%. Relaxed to >50% for older/high-risk adults, paired with tighter hypoglycemia protection.

Question 39

Ketone testing and interpreting blood beta-hydroxybutyrate (BHB)

Accepted Answer

Blood BHB (quantitative) is ADA-preferred over urine ketone strips (lags true status). Test when glucose is persistently >240 mg/dL, during illness, or with DKA symptoms. Interpretation: <0.6 mmol/L normal; 0.6-1.5 mild-moderate (follow sick-day plan); 1.6-3.0 high risk (contact care team); >3.0 high likelihood of DKA (seek emergency care).

Question 40

ADA hypoglycemia levels

Accepted Answer

Level 1: 54-69 mg/dL — 'glucose alert value,' low enough to treat. Level 2: <54 mg/dL — clinically significant, neuroglycopenic symptoms begin. Level 3: any glucose value — severe, defined by need for assistance from another person (not by a specific number).

Question 41

The 15-15 Rule (Rule of 15) for non-severe hypoglycemia

Accepted Answer

For a conscious person with glucose <70 mg/dL who can swallow safely: consume 15 g fast-acting carbohydrate, wait 15 minutes, recheck glucose, and repeat if still <70 mg/dL. AID/hybrid closed-loop users typically need only 5-10 g, since the pump is already reducing insulin delivery.

Question 42

Treating severe (Level 3) hypoglycemia

Accepted Answer

When a person cannot safely swallow, is unconscious, or is seizing, give glucagon (nasal spray, prefilled autoinjector/syringe, or reconstituted emergency kit) — not oral carbohydrate. Position the person on their side afterward (vomiting is common) and call emergency services if there's no response within about 15 minutes.

Question 43

DKA vs. HHS diagnostic criteria

Accepted Answer

DKA: glucose usually >250 mg/dL, pH <7.3, bicarbonate <18 mEq/L, ketones positive (BHB ≥3.0 mmol/L), rapid onset over hours — typically type 1. HHS: glucose usually >600 mg/dL, pH ≥7.3, bicarbonate ≥15 mEq/L, ketones minimal/absent, gradual onset over days — typically type 2, older adults, higher mortality.

Question 44

Retinopathy screening schedule

Accepted Answer

Type 1 diabetes: initial dilated eye exam within 5 years of diagnosis. Type 2 diabetes: initial dilated eye exam AT diagnosis. Both: annual dilated exams thereafter (may extend to every 1-2 years if no retinopathy and glycemia at goal).

Question 45

Nephropathy screening and UACR categories

Accepted Answer

Annual UACR + eGFR starting at diagnosis (T2DM) or 5 years post-diagnosis (T1DM). UACR categories: normal <30 mg/g, moderately increased 30-299 mg/g, severely increased ≥300 mg/g. An ACE inhibitor/ARB is recommended for hypertension with moderately increased albuminuria, strongly recommended for severely increased albuminuria or eGFR <60.

Question 46

Neuropathy screening tools

Accepted Answer

10-gram monofilament (loss of protective sensation), 128-Hz tuning fork (vibration sense), pinprick sensation, and ankle reflexes — assessed on the same 5-year (T1DM) / at-diagnosis (T2DM) schedule as retinopathy and nephropathy, then annually.

Question 47

Charcot neuroarthropathy

Accepted Answer

An acute, non-infectious inflammatory process in a neuropathic foot presenting as warm, red, swollen, with a palpable pulse and disproportionately little pain — often mistaken for cellulitis or gout. Requires immediate immobilization/offloading (typically total contact casting) to prevent progressive bone/joint destruction ('rocker-bottom' deformity).

Question 48

Diabetes distress vs. depression

Accepted Answer

Diabetes distress is the emotional burden specific to living with and managing diabetes (frustration, guilt, burnout); it is distinct from, though it can overlap with, clinical depression. Screened with the Diabetes Distress Scale (DDS) or Problem Areas in Diabetes (PAID) scale, recommended at least annually.

Question 49

Pregnancy glycemic targets (preexisting or gestational diabetes)

Accepted Answer

Fasting plasma glucose <95 mg/dL; 1-hour postprandial <140 mg/dL; 2-hour postprandial <120 mg/dL; A1C <6% (or <7% if needed to prevent hypoglycemia). Preconception A1C goal: <6.5%. Insulin is the preferred pharmacologic agent throughout pregnancy.

Question 50

Gestational diabetes screening and postpartum follow-up

Accepted Answer

GDM is screened at 24-28 weeks' gestation via a one-step 75-g OGTT (any 1 value ≥ fasting 92, 1-hr 180, or 2-hr 153 mg/dL) or a two-step 50-g GCT followed by a 100-g OGTT (≥2 of 4 values met). Everyone with GDM should be tested for persistent diabetes with a 75-g OGTT 4-12 weeks postpartum using standard non-pregnancy criteria.

Free CDCES Exam Flashcards

Filter by Topic

Jump to Card

About These CDCES Flashcards

Topics Covered

Frequently Asked Questions

CDCES

Explore More CBDCE Diabetes Care Certifications

CBDCE BC-ADM Board Certified Advanced Diabetes Management

More From This Family